Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy	B-cell neoplasm, Burkitt lymphoma, Chronic Disease, DNA Virus Infections, Disease Attributes, Epstein-Barr virus infection, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Hodgkins lymphoma, Infections, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Lymphoma, B-Cell, Marginal Zone, Myeloproliferative Disorders, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, T-cell non-Hodgkin lymphoma, Tumor Virus Infections, acute myeloid leukemia, anemia, bone marrow disorder, hematologic disorder, histiocytosis, immune system disorder, immunoproliferative disorder, interdigitating dendritic cell sarcoma, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoplasmacytic lymphoma, lymphoproliferative syndrome, malignant histiocytosis, mantle cell lymphoma, myelodysplastic syndrome, myelodysplastic syndrome with excess blasts, myelodysplastic syndrome with single lineage dysplasia, myeloid leukemia, neoplasm, viral infectious disease	Active, not recruiting	Phase 2	2026-01-06		NCT03674411

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Masonic Cancer Center, University of Minnesota	48

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Masonic Cancer Center at University of Minnesota	Minneapolis	United States	12